September 10, 2025Frontiers in ImmunologyOpen Access

Effectiveness and safety of dupilumab in the treatment of pediatric atopic dermatitis: a real-world study from China

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Real-world assessment demonstrates dupilumab's efficacy in pediatric atopic dermatitis, highlighting its safety profile.

Dupilumab achieved EASI-75 in 68.97% of patients at Week 16, indicating significant clinical improvement in symptoms.
Key metrics included EASI, itch reduction of 68.17%, and a 77.4% improvement in quality of life over a median 33-week follow-up.
This real-world study involved 59 children with moderate-to-severe atopic dermatitis, focusing on safety and efficacy.
Dupilumab shows sustained effectiveness, but vigilance is needed for potential early paradoxical flares and rare reactions.

Xu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark